Hosted on MSN
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more. We bought car ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results